Abstract：
Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).
摘要：
分化型甲状腺癌与良好的预后相关。分化型甲状腺癌的治疗选择是手术，其次是放射性碘消融（碘-131）在部分患者和甲状腺素治疗在大多数患者。手术也是甲状腺髓样癌的主要治疗方法，和激酶抑制剂可能适用于某些不可切除的复发性或持续性疾病患者。间变性甲状腺癌几乎是致命的，和碘-131成像和放射性碘不能使用。当需要进行全身治疗时，靶向治疗是首选.本文介绍了NCCN有关甲状腺髓样癌和甲状腺未分化癌的治疗建议，分化型甲状腺癌的外科治疗（乳头状，卵泡,Hürthle细胞癌）。
